New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF ...
An altered structure that 'mimics' the active form of BRAF Around half of all cancers are associated with dysfunction of the MAPK pathway, a communication system that enables cells to integrate ...
(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have ...
CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic ...
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...
Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas. A new review article offers insights into patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results